Research programme: cancer immunotherapeutics - CARsgen

Drug Profile

Research programme: cancer immunotherapeutics - CARsgen

Alternative Names: CAR-CD19 T - CARsgen; CAR-CD19 T cells - CARsgen; CD19 Redirected Autologous Cells - CARsgen; CSG-002; CSG-004; CSG-005; CSG-007; CSG-CD19

Latest Information Update: 19 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CARsgen
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Gastric cancer; Glioblastoma; Haematological malignancies; Neuroblastoma; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 05 Oct 2017 Carsgen plans a phase I trial for CAR-CD19 T cells for B cell leukaemia/lymphoma (In adults, In the elderly) in China (NCT03302403)
  • 11 May 2017 CARsgen and Changhai Hospital plan a clinical pilot study for Gastric and Pancreatic cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease, In adults, In the elderly) in China (IV)(NCT03159819)
  • 13 Oct 2016 CARsgen Therapeutics and RenJi Hospital plan a phase I trial for B-cell lymphoma and B-cell leukaemia in China (IV) (NCT02933775)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top